- SPEARHEAD-1 enrolment on track; planning to launch ADP-A2M4 in 2022 in the US for people with synovial sarcoma -
- Next registration directed trial initiating with ADP-A2M4CD8 in 1H 2021 for patients with gastroesophageal cancers -
- Efficacy with SPEAR T-cells in multiple solid tumor indications validates MAGE-A4 as a significant cancer target -
- Plan for five new autologous products in the clinic including an HLA-independent TCR (HiT) and an enhanced tumor infiltrating lymphocyte (TIL) expressing IL-7 -
- First two allogeneic products in the clinic by 2024 including a MAGE-A4 targeted product and a HiT targeting mesothelin partnered with Astellas -
- Financial guidance updated: funded into early 2023 -
- Virtual Investor Day today from
“We will lay out the strategy confirming our leadership position as a company designing and delivering cell therapies for people with cancer,” said
Adaptimmune’s Virtual Investor Day will cover the following topics:
Opening Remarks by
- Strategic vision for
Adaptimmune and core value drivers for the next five years - Delivering TCR T-cell therapies and building the cell therapy company of the future
- MAGE-A4 is a target with large market potential across a broad range of solid tumor indications including synovial sarcoma, lung, head and neck, bladder, and gastroesophageal cancers
Synovial sarcoma care: the need for cell therapy
- Dejka Araujo, M.D. (Professor in the
Department of Sarcoma Medical Oncology ,Division of Cancer Medicine of theMD Anderson Cancer Center ) will discuss the current treatment landscape and unmet medical need for people with synovial sarcoma
Driving towards delivery of two marketed products and two further BLAs by 2025
- An overview of plans to launch the first TCR T-cell therapy (ADP-A2M4) in synovial sarcoma as enrollment in the SPEARHEAD-1 trial is on track
- Plan to file a BLA with ADP-A2M4D8 in gastroesophageal cancers in 2024
- Potential addressable population across all tumor types with significant MAGE-A4 expression of ~39,000 patients per year in the US and EU factored for HLA-A21; additional BLA(s) projected with ADP-A2M4CD8 in tumor types beyond gastroesophageal cancers
- Additional BLA projected for ADP-A2AFP (first or next-generation CD8α) with a potential market opportunity of ~16,000 patients per year based on serum AFP expression1 and factoring for HLA-A2
- Plan to incorporate next-generation CD8α enhancement into SPEAR T-cells targeting AFP in a clinical trial next year
The importance of building an integrated cell therapy company for rapid execution and success
- An overview of the Company’s integrated structure with its leading capabilities for designing and delivering cell therapies
- Case studies demonstrating the value that this integrated approach has delivered: rapid execution of clinical programs, security of vector supply, reduction of costs, and learnings applied to the allogeneic platform
A rich cell therapy pipeline for the future over the next 5 years
- Focusing on curative intent: leveraging translational insights for best next-generation products:
- Positioning multiple enhancements for next-generation SPEAR T-cells including:
- ADP-A2M4 SPEAR T-cells co-expressing IL-7, IL-15, dnTGFβ, and/ or PDE7
- Enhancing SPEAR T-cells with IL-7 for proliferation and survival and CCL19 for migration into tumor in collaboration with Noile-Immune
- Enhancing SPEAR T-cells using transmembrane and surface immunoregulatory mechanisms with Alpine Immune Sciences
- Focusing on enabling mainstream access – broadening patient coverage and patient access:
- Plans to expand into HLAs beyond A2 to increase the addressable patient population
- Bringing forward HiT candidates for multiple targets including GPC3
- Announcing collaboration with leading TIL therapy center (CCIT,
Denmark ) for nextgeneration TILs co-expressing IL-7 - Bringing two allogeneic targets into the clinic:
- In-house MAGE A4 targeted iPSC T-cell products
- Mesothelin, a target expressed in multiple solid tumors, named as first HiT target in partnership with Astellas
An update on the Company’s financial position
- Total liquidity position of
$400 million as ofSeptember 30, 2020 - Current cash runway into early 2023
The Virtual Investor Day will also include two Q&A sessions.
About
Forward-Looking Statements
This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Quarterly Report on Form 10-Q filed with the
Media Relations:
T: +44 1235 430 583
M: +44 7718 453 176
Sebastien.Desprez@adaptimmune.com
Investor Relations:
T: +1 215 825 9310
M: +1 215 460 8920
Juli.Miller@adaptimmune.com
________________
1 Mortality figures based on
Source:
2020 GlobeNewswire, Inc., source